-The Telegraph New Delhi: The Supreme Court today ticked off the government for "dilly dallying" on an affordable drug pricing policy, following a petition that said the delay was aimed at pushing through suggestions of the powerful manufacturers' lobby. A bench of Justices G.S. Singhvi and Gopala Gowda asked the Centre to respond within six weeks. The All India Drug Action Network (AIDAN) had filed the application saying the government was delaying a...
More »SEARCH RESULT
Ahead of World Hepatitis Day, UN urges greater efforts to fight ‘silent epidemic’
-The United Nations Only one-third of the world's countries have national strategies for viral hepatitis, the United Nations health agency today said urging Governments to scale up measures to tackle this ‘silent epidemic,' in particular the five types that, over time, cause chronic and debilitating illnesses. "The fact that many hepatitis B and C infections are silent, causing no symptoms until there is severe damage to the liver, points to the urgent...
More »New drug pricing creates artificial scarcity-Shyama Rajagopal
-The Hindu Kochi: An artificial scarcity of drugs looms large with the new drug pricing regime, slashing prices for 348 essential drugs, set to prevail from July 29. Many retailers who stock medicines for a week are not picking up medicines and are keeping a minimum inventory. Some retailers said distributors were not making medicines available. It has sent medical retail stores into a tizzy about the fate of already available stocks. J.S....
More »Drug makers suffer an overdose of control-Bhupesh Bhandari
-The Business Standard The new price caps for 191 essential drugs are likely to introduce serious distortions in the market for these medicines The National Pharmaceutical Pricing Authority, or NPPA, has announced new price caps for 191 essential drugs that are 10 to 50 per cent lower than the current prices. Drug makers have 45 days to recall the earlier batches and send out new ones with the lower price tags. This...
More »Another bitter pill for patients-Sakthivel Selvaraj
-The Hindu The current market prices are essentially over and above the actual cost of production - a difference that could run from 100 per cent to 5,600 per cent, depending upon various therapeutic categories In a liberalised market economy, do we need price controls on drugs? Policymakers and the pharmaceutical industry do not think so. They believe that price controls are an inefficient tool that distorts resource allocation, squeezes revenue, reduces...
More »